Zoetis Inc.

Zoetis Inc. (NASDAQ: ZTS) is a global leader in the animal health industry with a legacy spanning nearly 75 years. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health solutions. Zoetis operates through two primary segments: the United States, which generated 54% of total revenue, and International operations, which accounted for 45% of revenue, with the remaining 1% derived from contract manufacturing services and human health products.

The company maintains a diversified portfolio across eight core animal species: dogs, cats and horses in the companion animal segment, and cattle, swine, poultry, fish and sheep in the livestock segment. Its product offerings span seven major categories including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represent approximately 70% of revenue while livestock products comprise 29%.

Zoetis operates a global manufacturing network of 21 owned or leased facilities across North America, Europe, Asia, Australia and South America, supplemented by relationships with over 90 contract manufacturing organizations. The company directly markets products in approximately 45 countries with distribution in more than 100 countries globally. As of December 31, 2025, Zoetis employed approximately 3,900 sales representatives and technical specialists, with approximately 1,700 employees dedicated to research and development operations headquartered in Kalamazoo, Michigan.

The company's intellectual property portfolio includes more than 5,500 granted patents and 1,600 pending patent applications filed across over 50 countries. Notable proprietary brands include Simparica and Simparica Trio for parasitic control, Apoquel for dermatology, Librela and Solensia for osteoarthritis pain management, and the Vetscan diagnostic platform. Zoetis was incorporated as a Delaware corporation in July 2012, following its separation from Pfizer Inc. The company's website is www.zoetis.com.